Ellen Ingalla

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

Elizabeth A. Punnoose, Franklin Peale, Erwin R. Boghaert et al. · Molecular Cancer Therapeutics · 2016 · 307 citations

Hematological Malignancy, Tumor Biology, Medicine +11

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Jane Guan, Wei Zhou, Marc Hafner et al. · Cell · 2019 · 215 citations · Full text

Signal Transduction, Endocrine Mechanism, Medicine +8

Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial

Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason et al. · Blood · 2019 · 133 citations · Full text

GDC-9545 (Giredestrant): A Potent and Orally Bioavailable Selective Estrogen Receptor Antagonist and Degrader with an Exceptional Preclinical Profile for ER+ Breast Cancer

Jun Liang, Robert A. Blake, Jae H. Chang et al. · Journal of Medicinal Chemistry · 2021 · 130 citations · Full text

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

James D. Joseph, Beatrice Darimont, Wei Zhou et al. · eLife · 2016 · 117 citations · Full text

Diverse Models, Breast Oncology, Erα Signaling +16